Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Tpoxx (tecovirimat) is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg.
• This summary is based on the review of six systematic review(s)/meta-analysis(es). ^[1-6]
• General Effectiveness Findings: Tecovirimat was used to treat 61 individuals with mpox, achieving a high rate of complete symptom resolution at 83.1%, and was beneficial in several severe cases.
• Comparative Effectiveness: Tecovirimat was more frequently used and showed better outcomes compared to other antivirals like cidofovir (used in 7 individuals) and brincidofovir (used in 3 individuals, which was associated with adverse effects leading to discontinuation).
• Effectiveness in Specific Populations: There were no randomized controlled trials (RCTs) assessing the effectiveness of tecovirimat in children or pregnant individuals, although observational studies reported uneventful treatment in these groups.
• Tecovirimat has not shown serious safety signals in mpox treatment, based on very low-certainty evidence from non-randomized studies, and no major safety concerns were reported in other studies.
• Brincidofovir (BCV) was associated with elevated hepatic panels and raised alanine aminotransferase (ALT) levels, leading to treatment discontinuation in all treated individuals, whereas tecovirimat did not show similar safety concerns.
• There is no population types or subgroups information available in the reviewed studies.